Background A previous phase 3 study showed that lumacaftor–ivacaftor was generally safe
and well tolerated over 24 weeks of treatment in children aged 2–5 years with cystic fibrosis …

Background The safety and efficacy of 24 weeks of lumacaftor–ivacaftor combination
therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR …

Background The efficacy, safety, and tolerability of lumacaftor and ivacaftor are established
in patients aged 6 years and older with cystic fibrosis, homozygous for the F508del-CFTR …

Background Lumacaftor and ivacaftor combination treatment showed efficacy in patients
aged 12 years or older with cystic fibrosis homozygous for F508del-cystic fibrosis …

Rationale: Previous phase 3 trials showed that treatment with lumacaftor/ivacaftor was safe
and efficacious in people aged⩾ 2 years with cystic fibrosis (CF) homozygous for the …

Rationale: Lumacaftor–ivacaftor is a CFTR (cystic fibrosis transmembrane conductance
regulator) modulator combination recently approved for patients with cystic fibrosis (CF) …

Background The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy
was shown in two randomised controlled trials (RCTs)—TRAFFIC and TRANSPORT—in …

Background Ivacaftor has been shown to be a safe, effective treatment for cystic fibrosis in
patients aged 6 years or older with a CFTR gating mutation. We aimed to assess the safety …

Rationale: Combination lumacaftor/ivacaftor has been shown to improve lung function and
other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for …

Introduction: Lumacaftor-ivacaftor is indicated for treatment of cystic fibrosis (CF) in patients
homozygous for the Phe-508del cystic fibrosis transmembrane conductance regulator …